

Abecma® (idecabtagene vicleucel) (Intravenous)

Document Number: IC-0598

Last Review Date: 11/04/2025

Date of Origin: 05/03/2021

Dates Reviewed: 05/2021, 10/2021, 11/2021, 08/2022, 11/2023, 06/2024, 11/2024, 11/2025

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for one treatment course (1 dose).
- Renewal: Prior authorization validity may NOT be renewed.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 1 billable unit (1 dose of up to 510 million autologous CAR-positive viable T-cells)

III. Initial Approval Criteria ¹

Submission of supporting clinical documentation (including but not limited to medical records, chart notes, lab results, and confirmatory diagnostics) related to the medical necessity criteria is REQUIRED on all requests for authorizations. Records will be reviewed at the time of submission as part of the evaluation of this request. Please provide documentation related to diagnosis, step therapy, and clinical markers (i.e., genetic, and mutational testing) supporting initiation when applicable. Please provide documentation via direct upload through the PA web portal or by fax. Failure to submit the medical records may result in the denial of the request due to inability to establish medical necessity in accordance with policy guidelines.

Prior authorization validity is provided in the following conditions:

- Patient is at least 18 years of age; **AND**
- Patient has not received prior chimeric antigen receptor (CAR)-T cell therapy; **AND**
- Patient does not have an active infection or inflammatory disorder; **AND**
- Patient has not received live vaccines within 6 weeks prior to the start of lymphodepleting chemotherapy, and will not receive live vaccines during idecabtagene vicleucel treatment, and until immune recovery following treatment; **AND**
- Patient has been screened for cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) in accordance with clinical guidelines prior to collection of cells (leukapheresis); **AND**
- Prophylaxis for infection will be followed according to standard institutional guidelines; **AND**
- Used as single agent therapy (*not applicable to lymphodepleting or additional chemotherapy while awaiting manufacture*); **AND**

- Patient does not have known central nervous system (CNS) involvement with myeloma or a history or presence of clinically relevant CNS pathology; **AND**
- Patient does not have active or a history of plasma cell leukemia; **AND**
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; **AND**

Multiple Myeloma † ‡ Φ^{1-3,7}

- Patient has relapsed or refractory disease*; **AND**
 - Patient has received at least two (2) prior lines of therapy, including a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib, etc.), an immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide, etc.), and an anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab, etc.); **OR**
 - Patient has received at least three (3) prior lines of therapy

**Regimen may also be used for the treatment of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, Skin changes (POEMS), Monoclonal Immunoglobulin Deposition Disease (MIDD), and plasma cell-related Monoclonal Gammopathy of Renal Significance (MGRS)*

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria

Duration of authorization has not been exceeded (refer to Section I)

V. Dosage/Administration¹

Indication	Dose
Multiple Myeloma	<p><u>Lymphodepleting chemotherapy:</u></p> <ul style="list-style-type: none"> • Administer cyclophosphamide 300 mg/m² and fludarabine 30 mg/m² intravenously daily for three days. <p><u>Abecma infusion:</u></p> <ul style="list-style-type: none"> • Infuse 2 days after completion of lymphodepleting chemotherapy. Delay the infusion up to 7 days if a patient has unresolved serious adverse events (especially pulmonary events, cardiac events, or hypotension), active infections, or inflammatory disorders. • A single dose of Abecma contains a cell suspension of 300 to 510 x 10⁶ chimeric antigen receptor (CAR)-positive T cells in one or more infusion bags.
<p>For autologous use only. For intravenous use only.</p> <ul style="list-style-type: none"> • Abecma is prepared from the patient’s peripheral blood mononuclear cells (PBMCs), which are obtained via a standard leukapheresis procedure. • One treatment course consists of lymphodepleting chemotherapy followed by an infusion of one or more bags of Abecma. • Confirm Abecma availability prior to starting the lymphodepleting regimen. • Confirm the patient’s identity with the patient identifiers on the shipper and the respective Certificate of Release for Infusion (RFI Certificate) prior to infusion. 	
<p><u>Premedication:</u></p>	

- Premedicate with acetaminophen (650mg orally) and diphenhydramine (12.5 mg IV, 25-50 mg orally, or another H1-antihistamine) 30-60 minutes prior to infusion. Avoid prophylactic systemic corticosteroids which may interfere with Abecma activity.

Monitoring after infusion:

- Monitor patients at least daily for 7 days following infusion for signs and symptoms of cytokine release syndrome (CRS) and neurologic toxicities.
- Instruct patients to remain within proximity of a healthcare facility for at least 2 weeks following infusion.
- Instruct patients to refrain from driving for at least 2 weeks following infusion.

- Store infusion bag in the vapor phase of liquid nitrogen (less than or equal to minus 130°C). Thaw prior to infusion.
- In case of manufacturing failure, a second manufacturing may be attempted.
- Additional chemotherapy (not the lymphodepletion) may be necessary while the patient awaits the product.
- Ensure that a minimum of 2 doses of tocilizumab and emergency equipment are available prior to infusion and during the recovery period.
- Abecma contains human blood cells that are genetically modified with replication-incompetent, self-inactivating lentiviral vector. Follow universal precautions and local biosafety guidelines for handling and disposal to avoid potential transmission of infectious diseases.

VI. Billing Code/Availability Information

HCPCS Code:

- Q2055 – Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose

NDC:

- Abecma suspension for intravenous infusion [A single dose of ABECMA contains a cell suspension of 300 to 510 x 10⁶ CAR-positive T cells in one or more infusion bags]:
 - 50 mL, 250 mL, and 500 mL infusion bags and metal cassettes: 59572-0515-xx

VII. References

1. Abecma [package insert]. Summit, NJ; Celgene Corporation, a Bristol-Myers Squibb Company, September 2025. Accessed October 2025.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) iclecabtagene vicleucel. National Comprehensive Cancer Network, 2025. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed October 2025.
3. Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med*. 2021 Feb 25;384(8):705-716. Doi: 10.1056/NEJMoa2024850.
4. Majzner RG, Mackall CL. Tumor Antigen Escape from CAR T-cell Therapy. *Cancer Discov* 2018;8:1219-1226.
5. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. *Blood* 2014; 124(2): 188-95. Errata in *Blood*: 2015;126(8):1048. And 2016;128(11):1533.

6. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol* 2016; 17(8): e328-46.
7. Rodríguez-Otero P, Ailawadhi S, Arnulf B, et al. B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL. *Hemasphere*. 2023 May 9;7(Suppl):7-8. Doi: 10.1097/01.HS9.0000936124.56965.24. PMID: PMC10171743.

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	Yes: Consider for PA
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma, in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.32	Solitary plasmacytoma in relapse
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15,

§50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC